{"schema_version":"secwatch.filing_event.v1","accession":"0001739104-26-000040","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2026-08-05T10:27:37+00:00","discovered_at":"2026-08-05T10:30:01.111677+00:00","generated_at":"2026-08-05T10:30:06.185666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Elanco Q2 revenue up 10% to $1.37B; raises full-year guidance on innovation momentum","bullets":["Q2 revenue $1,368M (+10% YoY); organic constant currency growth 8%.","Adjusted EPS $0.34 (+31% YoY); reported EPS $0.11 vs $0.02.","Full-year 2026 guidance raised: revenue $5.09B-$5.14B, Adj EBITDA $1.01B-$1.035B, Adj EPS $1.10-$1.16.","Innovation revenue target raised to $1.25B; net leverage ratio improved to 3.1x, targeting ~3.0x year-end.","Pet Health revenue +12% driven by Zenrelia and Credelio Quattro; Farm Animal +9%."],"urls":{"canonical":"https://secwatch.observer/filing/0001739104-26-000040","json":"https://secwatch.observer/filing/0001739104-26-000040.json","markdown":"https://secwatch.observer/filing/0001739104-26-000040.md","text":"https://secwatch.observer/filing/0001739104-26-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/0001739104-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/elan-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T10:30:06.185666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}